COTELLIC (cobimetinib), anti-MEK, protein kinase inhibitor

ONCOLOGY - New medicinal product
Opinions on drugs - Posted on May 25 2016

Reason for request

Inclusion

Moderate improvement in the first-line treatment of unresectable or metastatic melanoma, in patients with a BRAF V600 mutation

  • COTELLIC now has Marketing Authorisation in combination with vemurafenib, in the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
  • Its combination with vemurafenib (ZELBORAF) improves progression-free survival (+3.7 months) and overall survival (+4.9 months) in comparison with vemurafenib alone.
  • Like the trametinib/dabrafenib (MEKINIST/TAFINLAR) combination, the cobimetinib/vemurafenib combination is a first-line treatment in this indication.

Clinical Benefit

Substantial

-


Clinical Added Value

moderate

-


Therapeutic use

-

-

 

Contact Us

Évaluation des médicaments